• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加强英国的癌症临床研究。

Strengthening clinical cancer research in the United Kingdom.

机构信息

National Institute for Health Research Clinical Research Network Coordinating Centre, Leeds, UK.

出版信息

Br J Cancer. 2011 May 10;104(10):1529-34. doi: 10.1038/bjc.2011.69. Epub 2011 Mar 1.

DOI:10.1038/bjc.2011.69
PMID:21364584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3101916/
Abstract

BACKGROUND

In 1999, 270,000 cases of cancer were registered in the United Kingdom, placing a large burden on the NHS. Cancer outcome data in 1999 suggested that UK survival rates were poorer than most other European countries. In the same year, a Department of Health review noted that clinical trials accrual was poor (<3.5% of incident cases) and hypothesised that increasing research activity might improve outcomes and reduce the variability of outcomes across England. Thus, the National Cancer Research Network (NCRN) was established to increase participation in cancer clinical research.

METHODS

The NCRN was established in 2001 to provide a robust infrastructure for cancer clinical research and improvements in patient care. Remit of NCRN is to coordinate, support and deliver cancer clinical research through the provision of research support staff across England. The NCRN works closely with similar networks in Scotland, Wales and the Northern Ireland. A key aim of NCRN is to improve the speed of research and this was also assessed by comparing the speed of study delivery of a subset of cancer studies opening before and after NCRN was established.

RESULTS

Patient recruitment increased through NCRN, with almost 32,000 (12% of annual incident cases) cancer patients being recruited each year. Study delivery has improved, with more studies meeting the recruitment target - 74% compared with 39% before NCRN was established.

CONCLUSION

The coordinated approach to cancer clinical research has demonstrated increased accrual, wide participation and successful trial delivery, which should lead to improved outcomes and care.

摘要

背景

1999 年,英国登记了 27 万例癌症病例,这给国民保健制度(NHS)带来了巨大的负担。1999 年的癌症预后数据表明,英国的生存率比大多数其他欧洲国家差。同年,卫生部的一项审查指出,临床试验的入组率很低(<3.5%的新发病例),并假设增加研究活动可能会改善结果并减少英格兰各地结果的变异性。因此,成立了国家癌症研究网络(NCRN)以增加癌症临床研究的参与度。

方法

NCRN 成立于 2001 年,旨在为癌症临床研究提供强大的基础设施,并改善患者的护理。NCRN 的任务是通过在英格兰各地提供研究支持人员,协调、支持和开展癌症临床研究。NCRN 与苏格兰、威尔士和北爱尔兰的类似网络密切合作。NCRN 的一个主要目标是提高研究速度,这也通过比较 NCRN 成立前后开始的一组癌症研究的研究交付速度来评估。

结果

通过 NCRN,患者的招募人数有所增加,每年有近 32000 名(占年发病例的 12%)癌症患者被招募。研究的交付情况有所改善,更多的研究达到了招募目标-74%,而 NCRN 成立前为 39%。

结论

癌症临床研究的协调方法已经证明了入组人数的增加、广泛的参与和成功的试验交付,这应该会导致结果和护理的改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/9b147d3fc171/bjc201169f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/f3c647d1276a/bjc201169f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/d70154bbec26/bjc201169f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/28130e59ffe0/bjc201169f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/7f61d5491c3e/bjc201169f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/9b147d3fc171/bjc201169f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/f3c647d1276a/bjc201169f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/d70154bbec26/bjc201169f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/28130e59ffe0/bjc201169f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/7f61d5491c3e/bjc201169f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3218/3101916/9b147d3fc171/bjc201169f5.jpg

相似文献

1
Strengthening clinical cancer research in the United Kingdom.加强英国的癌症临床研究。
Br J Cancer. 2011 May 10;104(10):1529-34. doi: 10.1038/bjc.2011.69. Epub 2011 Mar 1.
2
An evaluation of the introduction of Clinical Trial Officer roles into the cancer clinical trial setting in the UK.对在英国癌症临床试验环境中引入临床试验官员角色的评估。
Eur J Cancer Care (Engl). 2005 Dec;14(5):448-56. doi: 10.1111/j.1365-2354.2005.00611.x.
3
High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.高医院研究参与度与改善的结直肠癌生存结局:一项基于人群的研究。
Gut. 2017 Jan;66(1):89-96. doi: 10.1136/gutjnl-2015-311308. Epub 2016 Oct 19.
4
Research-intensive cancer care in the NHS in the UK.英国国民保健制度中的以研究为基础的癌症护理。
Ann Oncol. 2011 Nov;22 Suppl 7:vii29-vii35. doi: 10.1093/annonc/mdr423.
5
The UK clinical research network--has it been a success for dermatology clinical trials?英国临床研究网络——它在皮肤病学临床试验中取得成功了吗?
Trials. 2011 Jun 16;12:153. doi: 10.1186/1745-6215-12-153.
6
Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.心脏康复计划的提供、接受情况及成本:改善对代表性不足群体的服务
Health Technol Assess. 2004 Oct;8(41):iii-iv, ix-x, 1-152. doi: 10.3310/hta8410.
7
Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group.英格兰青少年和青年纳入国家癌症研究网络临床试验的比例:国家癌症研究所(NCRI)青少年和青年临床研究发展小组的报告。
Br J Cancer. 2008 Dec 16;99(12):1967-74. doi: 10.1038/sj.bjc.6604751. Epub 2008 Nov 25.
8
The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015.2015 年英格兰、威尔士、苏格兰、北爱尔兰和英国归因于可改变风险因素的癌症比例。
Br J Cancer. 2018 Apr;118(8):1130-1141. doi: 10.1038/s41416-018-0029-6. Epub 2018 Mar 23.
9
Civil conflict in Northern Ireland and the prevalence of psychiatric disturbance across the United Kingdom: a population study using the British household panel survey and the Northern Ireland household panel survey.北爱尔兰的内战与全英国精神障碍的患病率:一项使用英国家庭调查面板和北爱尔兰家庭调查面板的人口研究。
Int J Soc Psychiatry. 2007 Sep;53(5):397-407. doi: 10.1177/0020764007078340.
10
Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials.可得、易接近、知晓、恰当、可接受:提高青少年和青年癌症试验参与度的策略。
Lancet Oncol. 2014 Jul;15(8):e341-50. doi: 10.1016/S1470-2045(14)70113-5.

引用本文的文献

1
Advancing Academic Cancer Clinical Trials Recruitment in Canada.推进加拿大癌症临床研究的招募工作。
Curr Oncol. 2021 Jul 28;28(4):2830-2839. doi: 10.3390/curroncol28040248.
2
Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.FLT3 突变型 AML 患者需要参加针对 FLT3 的靶向治疗临床试验。
Blood Adv. 2019 Dec 10;3(23):4055-4064. doi: 10.1182/bloodadvances.2019000532.
3
Co-enrolment of Participants into Multiple Cancer Trials: Benefits and Challenges.参与者同时参加多项癌症试验:益处与挑战。

本文引用的文献

1
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.截至2007年英格兰和威尔士基于人群的癌症生存趋势:对英格兰国民健康服务癌症计划的评估。
Lancet Oncol. 2009 Apr;10(4):351-69. doi: 10.1016/S1470-2045(09)70028-2. Epub 2009 Mar 19.
2
Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.参与随机对照试验的患者与接受类似干预但未参与试验的类似患者的结局比较。
Cochrane Database Syst Rev. 2008 Jul 16;2008(3):MR000009. doi: 10.1002/14651858.MR000009.pub4.
3
Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e126-e133. doi: 10.1016/j.clon.2017.02.014. Epub 2017 Mar 14.
4
Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre.在一家地区癌症中心,晚期胰腺腺癌患者从分散护理过渡到集中护理后的治疗结果。
Br J Cancer. 2017 Feb 14;116(4):424-431. doi: 10.1038/bjc.2016.406. Epub 2017 Jan 12.
5
The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database.评估PET成像在肿瘤学中诊疗作用的临床试验概况:来自ClinicalTrials.gov数据库分析的见解
Theranostics. 2017 Jan 1;7(2):390-399. doi: 10.7150/thno.17087. eCollection 2017.
6
High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.高医院研究参与度与改善的结直肠癌生存结局:一项基于人群的研究。
Gut. 2017 Jan;66(1):89-96. doi: 10.1136/gutjnl-2015-311308. Epub 2016 Oct 19.
7
Establishing an infrastructure to support the development and delivery of clinical research in patients with kidney disease.建立一个基础设施,以支持肾病患者临床研究的开展与实施。
Clin Med (Lond). 2015 Oct;15(5):415-9. doi: 10.7861/clinmedicine.15-5-415.
8
The systemic immune response to trauma: an overview of pathophysiology and treatment.创伤的全身免疫反应:病理生理学与治疗概述
Lancet. 2014 Oct 18;384(9952):1455-65. doi: 10.1016/S0140-6736(14)60687-5. Epub 2014 Oct 17.
9
Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry.生物等效性与生物利用度临床试验:来自美国国立卫生研究院临床试验.gov注册库的状态报告
J Bioequivalence Bioavailab. 2013 Nov 4;5:244-247. doi: 10.4172/jbb.1000167.
10
Lessons learnt recruiting to a multi-site UK cohort study to explore recovery of health and well-being after colorectal cancer (CREW study).从英国多中心队列研究招募中吸取的经验教训,该研究旨在探索结直肠癌(CREW 研究)后健康和幸福感的恢复情况。
BMC Med Res Methodol. 2013 Dec 28;13:153. doi: 10.1186/1471-2288-13-153.
Better outcomes for patients treated at hospitals that participate in clinical trials.
在参与临床试验的医院接受治疗的患者有更好的治疗结果。
Arch Intern Med. 2008 Mar 24;168(6):657-62. doi: 10.1001/archinternmed.2007.124.
4
Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study.随机试验的招募:试验入组与参与策略研究。STEPS研究。
Health Technol Assess. 2007 Nov;11(48):iii, ix-105. doi: 10.3310/hta11480.
5
The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK.“临床试验”指令对英国非商业性癌症试验成本及开展情况的影响。
Eur J Cancer. 2007 Jan;43(1):8-13. doi: 10.1016/j.ejca.2006.09.016. Epub 2006 Nov 21.
6
Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer.卵巢癌的治疗模式以及参与临床研究对其预后的影响。
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):183-91. doi: 10.1111/j.1525-1438.2005.15202.x.
7
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review.癌症患者在临床试验内和临床试验外接受治疗的结局比较:概念框架与结构化综述。
Lancet. 2004 Jan 24;363(9405):263-70. doi: 10.1016/S0140-6736(03)15383-4.
8
Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect".随机临床试验(短期内)对我们有益吗?关于“试验效应”的证据。
J Clin Epidemiol. 2001 Mar;54(3):217-24. doi: 10.1016/s0895-4356(00)00305-x.
9
Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.治疗方案能否改善最终结果?芬兰多发性骨髓瘤患者生存情况的一项研究。
BMJ. 1989 Oct 28;299(6707):1069-72. doi: 10.1136/bmj.299.6707.1069.